Outsourced Pharma Webinars

  1. Standing Out In The Crowded Biopharmaceutical Contract Manufacturing Market
    3/14/2019

    Differentiating one’s CDMO offering from competitors is an essential component of gaining awareness, familiarity, and being awarded business. When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offering to the right audience at the right time. 

  2. A Systematic Approach To Extractables And Leachables: A Review Of Guidance From The Industry
    12/11/2018

    This presentation discusses the basic definitions of extractables and leachables, including details from a case study done using prefilled syringes and a second using a single-use bag.

  3. Cell-Based Assays In A GMP Environment: Approaches For Clinical And Commercial Stability Studies
    12/11/2018

    This presentation demonstrates that in vitro, cell-based assays is an indispensable tool to quantify the biological activities, and to support the potency tests, for bio therapeutics.

  4. Optimizing Your Plate-Based Assay Workflows
    11/27/2017

    Using workflow based software solutions to guide scientists through various processes in low to high throughput screening campaigns.

  5. Leveraging Machine Learning For Decision Making In The Lab
    11/27/2017

    This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.

  6. Looking Under The Hood Of The Unified Lab
    11/22/2017

    Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.

  7. Solvents, Polymers & Cyclones: Bioavailability Enhancement Through Spray-Dried Dispersions
    11/2/2017

    Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed.

  8. Challenges And Opportunities In The Development Of Biologic Drugs
    7/20/2017

    With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.

  9. Optimize Biologic Drug Development With The Power Of Scientific Informatics
    7/20/2017

    The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.

  10. Visibility and Oversight: What Paper Informed Consent Isn’t Offering You (Featuring Guest Speaker, Chesapeake IRB)
    3/8/2017

    Chesapeake IRB and CRF Health team up for a collaborative webinar to discuss informed consent oversight and visibility and why Top Pharma is turning to Electronic Informed Consent (eConsent) to exceed in these areas.